Article
A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD).
Leukemia research - 1 Mar 2008
Koren-Michowitz Maya, Shimoni Avichai, Vivante Asaf, Trakhtenbrot Luba, Rechavi Gideon, Amariglio Ninette, Loewenthal Ron, Nagler Arnon, Cohen Yoram
Abstract excerpt
JAK2 V617F mutation is found in a high proportion of MPD patients. We developed a quantitative assay for the detection of the JAK2 mutation and demonstrated its clinical utility in MPD patients who underwent SCT. Sixty percent of the patients were JAK2 V617F positive prior to the SCT (mean mutati...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.